149 related articles for article (PubMed ID: 11777551)
1. Chemokine receptor expression on B cells and effect of interferon-beta in multiple sclerosis.
Sørensen TL; Roed H; Sellebjerg F
J Neuroimmunol; 2002 Jan; 122(1-2):125-31. PubMed ID: 11777551
[TBL] [Abstract][Full Text] [Related]
2. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS.
Sørensen TL; Sellebjerg F
Neurology; 2001 Oct; 57(8):1371-6. PubMed ID: 11673573
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid.
Teleshova N; Pashenkov M; Huang YM; Söderström M; Kivisäkk P; Kostulas V; Haglund M; Link H
J Neurol; 2002 Jun; 249(6):723-9. PubMed ID: 12111306
[TBL] [Abstract][Full Text] [Related]
4. Selective suppression of chemokine receptor CXCR3 expression by interferon-beta1a in multiple sclerosis.
Sørensen TL; Sellebjerg F
Mult Scler; 2002 Apr; 8(2):104-7. PubMed ID: 11990865
[TBL] [Abstract][Full Text] [Related]
5. Expression of chemokine receptors in the different clinical forms of multiple sclerosis.
Martínez-Cáceres EM; Espejo C; Brieva L; Pericot I; Tintoré M; Sáez-Torres I; Montalban X
Mult Scler; 2002 Oct; 8(5):390-5. PubMed ID: 12356205
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse.
Mahad DJ; Lawry J; Howell SJ; Woodroofe MN
Mult Scler; 2003 Mar; 9(2):189-98. PubMed ID: 12708814
[TBL] [Abstract][Full Text] [Related]
7. gamma/delta T cells in multiple sclerosis: chemokine and chemokine receptor expression.
Murzenok PP; Matusevicius D; Freedman MS
Clin Immunol; 2002 Jun; 103(3 Pt 1):309-16. PubMed ID: 12173306
[TBL] [Abstract][Full Text] [Related]
8. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946
[TBL] [Abstract][Full Text] [Related]
9. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions.
Balashov KE; Rottman JB; Weiner HL; Hancock WW
Proc Natl Acad Sci U S A; 1999 Jun; 96(12):6873-8. PubMed ID: 10359806
[TBL] [Abstract][Full Text] [Related]
10. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis.
Salama HH; Kolar OJ; Zang YC; Zhang J
Mult Scler; 2003 Feb; 9(1):28-31. PubMed ID: 12617264
[TBL] [Abstract][Full Text] [Related]
11. Expression and functional activity of chemokine receptors in glatiramer acetate-specific T cells isolated from multiple sclerosis patient receiving the drug glatiramer acetate.
Høglund RA; Hestvik AL; Holmøy T; Maghazachi AA
Hum Immunol; 2011 Feb; 72(2):124-34. PubMed ID: 20977917
[TBL] [Abstract][Full Text] [Related]
12. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis.
Zang YC; Skinner SM; Robinson RR; Li S; Rivera VM; Hutton GJ; Zhang JZ
Mult Scler; 2004 Oct; 10(5):499-506. PubMed ID: 15471364
[TBL] [Abstract][Full Text] [Related]
13. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
14. Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.
Qu ZX; Pliskin N; Jensen MW; White D; Arnason BG
Arch Neurol; 2001 Jan; 58(1):87-90. PubMed ID: 11176940
[TBL] [Abstract][Full Text] [Related]
15. Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling.
Misu T; Onodera H; Fujihara K; Matsushima K; Yoshie O; Okita N; Takase S; Itoyama Y
J Neuroimmunol; 2001 Mar; 114(1-2):207-12. PubMed ID: 11240033
[TBL] [Abstract][Full Text] [Related]
16. CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis.
Sellebjerg F; Ross C; Koch-Henriksen N; Sørensen PS; Frederiksen JL; Bendtzen K; Sørensen TL
Mult Scler; 2005 Dec; 11(6):641-5. PubMed ID: 16320722
[TBL] [Abstract][Full Text] [Related]
17. Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells.
Kivisäkk P; Cotleur AC; Lee JC; Rudick RA; Ransohoff RM
J Neuroimmunol; 2003 Aug; 141(1-2):150-4. PubMed ID: 12965266
[TBL] [Abstract][Full Text] [Related]
18. [The use of rebif in the Moscow Municipal Multiple Sclerosis Center].
Popova EV; Boĭko AN; Davydovskaia MF; Demina TL; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):68-71. PubMed ID: 21916159
[TBL] [Abstract][Full Text] [Related]
19. Memory and naïve B-cell subsets in patients with multiple sclerosis.
Niino M; Hirotani M; Miyazaki Y; Sasaki H
Neurosci Lett; 2009 Oct; 464(1):74-8. PubMed ID: 19666086
[TBL] [Abstract][Full Text] [Related]
20. Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS.
Julià E; Edo MC; Horga A; Montalban X; Comabella M
Clin Immunol; 2009 Dec; 133(3):364-74. PubMed ID: 19740704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
